Last update 24 Mar 2025

Naproxen/Phosphatidylcholine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
PL-3100
Target
COXs
Action
inhibitors
Mechanism
COX inhibitors(Cyclooxygenases inhibitors)
Therapeutic Areas
Digestive System DisordersSkin and Musculoskeletal Diseases
Active Indication-
Inactive Indication
ArthritisGastrointestinal mucosal disorderPeptic Ulcer
Originator Organization
PLx Pharma, Inc.PLx Pharma, Inc.
Active Organization-
Inactive Organization
PLx Pharma, Inc.PLx Pharma, Inc.
Drug Highest PhaseDiscontinuedPhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC14H14O3
InChIKeyCMWTZPSULFXXJA-VIFPVBQESA-N
CAS Registry22204-53-1

Related

2
Clinical Trials associated with Naproxen/Phosphatidylcholine
NCT01139190
/ CompletedPhase 2
A Phase 2 Clinical Trial Evaluating the Incidence of Upper Gastrointestinal Mucosal Damage Following Administration of Either PL3100 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated GI Damage
NCT00966641
/ CompletedPhase 1/2
"A Single-Dose Crossover Oral Bioequivalence Study of PL 3100 and Naproxen in Healthy Adult Volunteers in the Fasted State"
100 Clinical Results associated with Naproxen/Phosphatidylcholine
Login to view more data
100 Translational Medicine associated with Naproxen/Phosphatidylcholine
Login to view more data
100 Patents (Medical) associated with Naproxen/Phosphatidylcholine
Login to view more data
100 Deals associated with Naproxen/Phosphatidylcholine
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Gastrointestinal mucosal disorderPhase 2
United States
PLx Pharma, Inc.PLx Pharma, Inc.
01 Jul 2010
Peptic UlcerPhase 2
United States
PLx Pharma, Inc.PLx Pharma, Inc.
01 Jul 2010
ArthritisPhase 2-
PLx Pharma, Inc.PLx Pharma, Inc.
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT01139190 (CTgov)
Phase 2
Peptic Ulcer | Gastrointestinal mucosal disorder
77
(PL3100)
fehbdyeald = tfwtxojnod ppexqixibf (ochzxrpdnh, qjyyxixojj - nckgpufdau)
View more
-
11 Apr 2016
(Naproxen)
fehbdyeald = hgctkkedia ppexqixibf (ochzxrpdnh, ojbjlcqwxm - phloemxbbb)
View more
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free